ADM, a leader in innovative solutions from nature, announced its agreement with Asahi Group Foods Corporation, a food company headquartered in Japan, to exclusively market and distribute Asahi Group's proprietary lactic acid-based postbiotic, Lactobacillus gasseri CP2305. Backed by eight human clinical trials1,2,3,4,5,6,7,8 and capable of targeting stress, mood, and sleep support, the introduction of the postbiotic to ADM's portfolio comes as products targeting mood/relaxation support grew at a double-digit CAGR of 13% from 2018-2023, with a category growth of nearly 34%9.

CHECK OUT MORE FOOD & BEVERAGE INDUSTRY NEWS

L. gasseri CP2305 is owned by the Asahi Group and was discovered through many years of research on Calpis-derived lactic acid bacteria. The agreement enables Asahi Group to strengthen its business in the area of lactic acid bacteria materials and meet increasing demand for diverse functional food products through ADM's large global network and R&D centers. Asahi Group will continue to use the ingredient in supplements and beverages sold in Japan. Beginning in March, ADM will expand L. gasseri CP2305 distribution to food manufacturers in North America, Europe and Asia.

L. gasseri CP2305 offers a new avenue for innovation in the health and wellness space, addressing the rising need for stress management and sleep quality solutions. It is a postbiotic with clinically documented evidence showing support for physiological functions that the gut-brain axis can influence.

Results from eight gold-standard, randomized, double-blind, placebo-controlled human clinical trials1,2,3,4,5,6,7,8 suggest that supplementing one's diet with L. gasseri CP2305 may support emotional well-being and reduced stress, better sleep efficiency, reduced time to fall asleep/reduced sleep latency, healthier overall sleep quality, and improved total duration of sleep1,2,3.

As a postbiotic, L. gasseri CP2305 can withstand numerous formulation environments, including tough conditions like high-heat or high-water content commonly associated with functional foods and on-trend dosage formats such as gummies.

In spring 2024, ADM published a study on probiotic Bifidobacterium longum CECT 7347 (ES1)* and postbiotic Bifidobacterium longum CECT 7347 (HT-ES1) in Gut Microbes, showing they may support overall gut and digestive health10. ADM also delivers unique support for aspects of metabolic health with BPL1™** (Bifidobacterium animalis subsp. lactis CECT 8145) probiotic and postbiotic11.

References

1 Nishida et al., 2017 Journal of Applied Microbiology 123:1561-1570 (2)
2 Nishida et al., 2017 Journal of Functional Foods 36:112–121 (3)
3 Nishida et al., 2019 Nutrients 11:1859 (4)
4 Nishida et al., 2021 Journal of Functional Foods 80:104426
5 Sawada et al., 2016 Food Research International 79:33-39
6 Sawada et al., 2019 Journal of Functional Foods 57:465–476
7 Sawada et al., 2022 Nutrients, 14:1695
8 Sugawara et al., 2016 Microbial Ecol Health Dis.
9 Euromonitor Retail Sales Data, Retail Value RSP, USD Million, Fixed 2023 Ex Rates, 2018-2023
10 Srivastava, S., et al., 2024 Gut Microbes. 16(1):2338322
11 Pedret, A., et al., 2019 Int J Obes (Lond). 43(9):1863‐1868
* Bifidobacterium longum CECT7347 (ES1) is used by ADM Biopolis under license from CSIC.
** BPL1™ is a trademark registered for Biopolis S.L. in the EU and other countries.